Vor Biopharma Inc
VOR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.16B
Close$
$39.86
82.1% upside
Current Fair Value
82.1% upsideUndervalued by 82.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.16 Billion |
|---|---|
| Enterprise Value | $1.05 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-70.5 |
| Beta | 1.72 |
| Outstanding Shares | 54,304,456 |
Return
| Return on Equity | -313.58% |
|---|---|
| Return on Assets | 130.50% |
| Return on Invested Capital | -32.24% |
Valuation & Multiples
| P/E Ratio | -0.07 |
|---|---|
| PEG | 0.07 |
| Price to Sales | - |
| Price to Book Ratio | -5.47 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.17 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.86
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.81
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 64,600▼ 63.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 89.55%▲ 15.06% |
|---|---|
| Total Invested | $895.27M▲ 24.89% |
| Investors Holding | 105▲ 24.00% |
ESG Score
No data
About Vor Biopharma Inc
88 employeesVor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the pote...